Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept

J Rheumatol. 2005 Apr;32(4):740-3.


Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / immunology
  • Arthritis, Juvenile / complications*
  • Arthritis, Juvenile / drug therapy
  • Disease-Free Survival
  • Etanercept
  • Female
  • Humans
  • Immunocompromised Host
  • Immunoglobulin G / adverse effects*
  • Immunoglobulin G / immunology
  • Lupus Nephritis / chemically induced*
  • Lupus Nephritis / immunology
  • Lupus Nephritis / pathology
  • Receptors, Tumor Necrosis Factor / immunology
  • Recombinant Fusion Proteins / adverse effects*
  • Recombinant Fusion Proteins / immunology
  • Vasculitis, Leukocytoclastic, Cutaneous / chemically induced*
  • Vasculitis, Leukocytoclastic, Cutaneous / immunology
  • Vasculitis, Leukocytoclastic, Cutaneous / pathology
  • Withholding Treatment


  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Etanercept